Salute e Benessere

Casino Group Communication

Casino Group Communication Paris, 29 October 2025Further to the article published today by Olivier Dauvers entitled “Casino: Kretinsky réinjecte de l’oxygène” (“Casino: Kretinsky injects new life”), Casino Group categorically denies the information that Daniel Kretinsky has “ injected €500 million into the retailer's accounts.” ***ANALYSTS AND INVESTORS CONTACTSCharlotte [email protected] Tél : +33 (0)6 89 19 88 [email protected] Tél : +33...
Nasdaq GlobeNewswire
29/10/2025

Jungbunzlauer Tricalcium Citrate Excipient Demonstrates Outstanding Results in…

"This collaboration with Professor Wagner and his workgroup from the Department of Pharmaceutical Technology and Biopharmaceutics at the University of Bonn underscores our commitment to rigorous science, innovation and product excellence," said Markus Gerhart, Senior Director Category Lead Minerals & Solutions at Jungbunzlauer. "Through validated research, we're proud to demonstrate that our TCC TB delivers reliable performance in direct compression, helping our customers…
PR Newswire
29/10/2025

Herb Extract Market to Reach $23.8 billion, Globally, by 2035 at 9.3% CAGR…

Request Sample of the Report on Herb Extract Market Forecast 2034 – https://www.alliedmarketresearch.com/request-sample/A194451 Request Sample of the Report on Herb Extract Market Forecast 2034 –https://www.alliedmarketresearch.com/request-sample/A194451 Market Introduction Herb extracts are natural bioactive compounds derived from plants, widely used in dietary supplements, pharmaceuticals, cosmetics, and food & beverages for their therapeutic, nutritional, and functional...
PR Newswire
29/10/2025

Novartis ianalumab first drug to reduce disease activity and patient burden in…

NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit 1 Data showed consistent improvements across secondary outcome measures, and a favorable safety profile 1 Novartis plans to submit to health authorities globally in early 2026 If approved, ianalumab could become first targeted treatment for this heterogeneous, systemic autoimmune diseaseBasel, October 29, 2025– Novartis today...
Nasdaq GlobeNewswire
29/10/2025

Clinical Analytics Market worth $81.32 billion by 2030 with 19.7% CAGR |…

Browse in-depth TOC on "Clinical Analytics Market" Browse in-depth TOC on "Clinical Analytics Market" 400 - Tables 50 - Figures 400 - Pages By use case,the healthcare use case segment accounted for significant growth in the clinical analytics market in 2024, driven by the increasing adoption of value-based care models and the growing demand for data-driven decision-making to improve patient outcomes. Healthcare providers are leveraging clinical analytics for clinical...
PR Newswire
29/10/2025

Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's…

"We are excited to partner with Nitto Denko Avecia, a recognized leader in therapeutic oligonucleotide manufacturing," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "This collaboration represents a significant milestone toward expanding the reach of our ECO Synthesis® Manufacturing Platform, through best-in-class CDMO collaborations." "We are excited to partner with Nitto Denko Avecia, a recognized leader in therapeutic oligonucleotide…
PR Newswire
29/10/2025

VentureMed Group Closes $28M Series C Funding to Accelerate Commercial Adoption…

In addition to expanded commercial infrastructure, the funding will also advance VentureMed's clinical program and support new product development, including new applications in adjacent vascular settings. In addition to expanded commercial infrastructure, the funding will also advance VentureMed's clinical program and support new product development, including new applications in adjacent vascular settings. "VentureMed is addressing one of the most persistent challenges in vascular…
PR Newswire
29/10/2025

Study Finds ELISAs in Milk Samples Less Reliable for Johne's Disease Detection…

Johne's disease costs the U.S. dairy industry an estimated $198 million annually (Journal of Dairy Science, Rasmussen et al., 2021). The disease, caused by the bacterium Mycobacterium avium subspecies paratuberculosis (MAP), progressively damages the gut of infected cattle, reducing nutrient absorption and milk yield. It spreads primarily through contaminated feces, milk or feed. Johne's disease costs the U.S. dairy industry an estimated$198 millionannually (Journal of Dairy Science,...
PR Newswire
29/10/2025

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

Click here to view the custom infographic of the Oncotelic Therapeutics editorial. Clickhere to view the custom infographic of the Oncotelic Therapeutics editorial. The pharmaceutical sector is at a critical turning point as it becomes increasingly clearthat even the most powerful cancer treatments depend on how effectively they reach tumors in therapeutic concentrations. Many promising oncology drugs underperform not because of inadequate mechanisms of action but because only a small...
PR Newswire
29/10/2025

Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley

COPENHAGEN, Denmark, October 29, 2025– Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5.20% of the shares and voting rights in Bavarian Nordic A/S as of October 23, 2025.About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox...
Nasdaq GlobeNewswire
29/10/2025

"World Hair Transplant Repair Day" Taking Place on 11/11 Shines Light on…

Case in point: earlier this month, Dubai police arrested a man running an illegal hair transplant clinic from an apartment. Case in point: earlier this month,Dubaipolice arrested a man running an illegal hair transplant clinic from an apartment. "These fraudulent, illicit hair transplant clinics operate under the guise of an established medical practice, luring unsuspecting patients with false or misleading advertising, rock-bottom prices and tempting travel packages," saidConradin…
PR Newswire
29/10/2025

Grupo Elfa and NUPCO sign agreement to support Saudi healthcare ecosystem with…

The MoU focuses on exploring joint opportunities in healthcare procurement, logistics, and digital efficiency, with an initial emphasis on the direct sourcing of medical disposables. NUPCO, as the national healthcare procurement and distribution hub, provides unparalleled access to an extensive network of hospitals, pharmacies, and warehousing infrastructure across Saudi Arabia. This partnership will connect NUPCO to Grupo Elfa's trusted global supplier network, diversifying sourcing channels…
PR Newswire
29/10/2025

Lycored Debuts New VAS Technology at SupplySide Global

Lycobeads VAS TM 10% is a leading formulation within the new VAS portfolio featuring lycopene, a standout nutraceutical ingredient renowned for its powerful antioxidant activity and its role in supporting cardiovascular health, skin protection and prostate function. Overall, VAS is a universal go-to solution that simplifies and streamlines formulation with one consistently high-performing product. Lycobeads VAS TM 10% is a leading formulation within the new VAS portfolio featuring lycopene, a...
PR Newswire
29/10/2025

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation as a presenting company at BIO-Europe 2025. The event, Europe’s premier life sciences partnering conference, will take place November 3–5, 2025, at the Vienna Exhibition and Congress Center (Messe Wien) in Vienna, Austria.Tiziana’s management...
Nasdaq GlobeNewswire
29/10/2025

OKYO Pharma to Present at BIO-Europe 2025 in Vienna

LONDON and NEW YORK, Oct.29, 2025(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma, will present at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria.BIO-Europe, one of the...
Nasdaq GlobeNewswire
29/10/2025

Thousand Oaks Biologics Showcases Integrated ADC CRDMO Solutions & Media…

Antibody-drug conjugates (ADCs) are a key driver of China's innovative drug globalization. Leveraging its end-to-end CRDMO model and international compliance qualifications, Thousand Oaks Biologics is positioned to address critical industry pain points, including R&D efficiency, scale-up costs, and regulatory risks. Its core competencies encompass a self-sufficient supply of critical raw materials, superior cost-control and efficiency, a rigorous quality management system, and an…
PR Newswire
29/10/2025

StickIt Clarifies Corporate Reorganization Share Consolidation and Proposed…

Although the transactions contemplated by the LOI will result in results in new shareholders holding greater than 50% of the voting securities of the Company, it is not expected to result in change of control of the Company. The transactions contemplated by the LOI are not expected to result in Fundamental Change (as defined in the Canadian Securities Exchange (the "CSE") policies), subject to the discretion of the CSE. Although the transactions contemplated by the LOI will result in…
PR Newswire
29/10/2025

Late-breaking iMODERN findings presented at TCT 2025 and published in the New…

3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant difference in major outcomes compared with waiting for follow-upAdditional results from the ILIAS ANOCA study highlight the sustained benefits of physiology-guided assessment and tailored medical therapy for patients with angina and no obstructive coronary arteries Amsterdam, the Netherlands –Royal...
Nasdaq GlobeNewswire
29/10/2025

CMR Surgical Adopts NVIDIA IGX THOR for AI-Powered, Next Generation Surgical…

CMR Surgical Adopts NVIDIA IGX THOR for AI-Powered, Next Generation Surgical Robotics ● Testing to focus on the potential to deliver real-time, AI-powered insights that improve patient outcomes and support continuous learning for surgeons Cambridge, UK – 29 October 2025,CMR Surgical (‘CMR’), the global surgical robotics business, today announces it is an early adopter of NVIDIA IGXThor as it evaluates its integration into the Versius Surgical Robotic System.IGX Thor is...
Nasdaq GlobeNewswire
29/10/2025

PARTNERSHIP OMRON HEALTHCARE UK & STROKE ASSOCIATION: Stroke Association and…

The growing stroke crisis in the UK The growing stroke crisis in the UK Stroke is the leading cause of complex adult disability and the fourth biggest cause of death in the UK. Every day, 240 people wake up to the impact of stroke in the UK. AFib, a common heart rhythm disorder, is a significant risk factor, increasing the likelihood of stroke by up to five times (*1). However, AFib often goes undetected due to a lack of symptoms (*2), making regular monitoring crucial for early intervention...
PR Newswire
29/10/2025

Photocure ASA: Results for the third quarter of 2025

The company continued to execute on its plan to expand blue light cystoscopy (BLC®) use in Q3 2025 with the installation of 14 new Saphira towers in the U.S. — 7 new accounts and 7 blue light tower upgrades. In addition, due to increasing demand, ForTec has acquired and deployed 6 additional BLC towers, bringing the total number of mobile BLC towers to 24. With the increasing momentum provided by ForTec's mobile solution, Photocure had 373 active accounts in the U.S. at the end of the quarter…
PR Newswire
29/10/2025

Smartee and Straumann Announce Strategic Partnerships to Accelerate Innovation…

Florian Kirsch, Executive Vice President, Global Head IDT of Straumann Group, said: "We are proud to join forces with a strong global partner like Smartee. Together we will accelerate innovation in orthodontics and build a platform that makes high-quality, predictable treatment more accessible to doctors and patients worldwide." Florian Kirsch , Executive Vice President, Global Head IDT of Straumann Group, said: "We are proud to join forces with a strong global partner like…
PR Newswire
29/10/2025

Insilico Showcases Advanced Generative Biologics Engine in Breakthrough 72-Hour…

In a recent pioneering study, Insilico has demonstrated the remarkable potential of generative biologics to rapidly design peptides targeting GLP1R—the receptor modulated by blockbuster diabetes drugs such as Ozempic. Leveraging its Biology42: Generative Biologics engine, Insilico's R&D team generated over 5,000 novel peptides within a 72-hour cycle, without referencing any known GLP1R binders. From these, 20 top candidates were selected for synthesis and wet-lab evaluation based on…
PR Newswire
29/10/2025

Addex Increases Issued Share Capital to Create Treasury Shares

Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, October 29, 2025-Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN),a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that 34,300,000 new registered shares at a nominal value of CHF 0.01 have been issued and fully subscribed by Addex Pharma S.A, its 100% wholly-owned subsidiary. The new shares, issued from...
Nasdaq GlobeNewswire
29/10/2025
Altri  Comunicati